Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Onglyza's label should flag heart failure risks, FDA panel says
Onglyza's label should flag heart failure risks, FDA panel says
Onglyza's label should flag heart failure risks, FDA panel says
Submitted by
admin
on April 15, 2015 - 8:49am
Source:
Fierce Pharma
News Tags:
Onglya
diabetes
FDA
AstraZeneca
Headline:
Onglyza's label should flag heart failure risks, FDA panel says
Do Not Allow Advertisers to Use My Personal information
